Bain Capital teams with Pfizer to create new neuroscience-focused company
October 23, 2018 at 07:01 AM EDT
Pfizer announced in January it planned to shut down early- and mid-stage neuroscience drug development. But now it's teamed with investment firm Bain Capital to create a new company composed of its neuroscience assets and funded with $350 million from Bain. Its name: Cerevel Therapeutics.
